Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone
Abeona Therapeutics (ABEO) reported a 31% revenue increase to $11.4 million for the second quarter of 2026, as its gene therapy ZEVASKYN treated 12 patients. The company has expanded its treatment network to seven sites, including Cincinnati Children's Hospital. ZEVASKYN now has NTAP status, providing reimbursement coverage in 40% of the patient population's states.
The company's R&D spending decreased to $5 million, and SG&A costs dropped to $15.8 million. However, the quarter saw a widened net loss of $20.2 million and manufacturing issues with one low-yield and one out-of-specification batch. The market remains undecided on weighing ZEVASKYN's progress against its operational challenges.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
